ProShare Advisors LLC Buys 2,485 Shares of Cencora, Inc. $COR

ProShare Advisors LLC raised its stake in Cencora, Inc. (NYSE:COR) by 6.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,445 shares of the company’s stock after purchasing an additional 2,485 shares during the quarter. ProShare Advisors LLC’s holdings in Cencora were worth $13,660,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Oakworth Capital Inc. purchased a new stake in Cencora in the 4th quarter valued at $26,000. Elyxium Wealth LLC purchased a new position in Cencora during the 4th quarter worth $27,000. Archer Investment Corp grew its stake in shares of Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares in the last quarter. Optima Capital LLC purchased a new stake in shares of Cencora in the fourth quarter valued at about $31,000. Finally, IAG Wealth Partners LLC bought a new position in shares of Cencora during the third quarter valued at about $30,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR stock opened at $264.79 on Thursday. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The firm has a market cap of $51.52 billion, a price-to-earnings ratio of 20.31, a P/E/G ratio of 1.23 and a beta of 0.64. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The firm’s 50-day simple moving average is $308.93 and its two-hundred day simple moving average is $337.71.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion for the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s revenue was up 3.9% on a year-over-year basis. During the same period in the prior year, the company earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities analysts forecast that Cencora, Inc. will post 17.76 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Wells Fargo & Company cut their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a report on Monday, May 11th. Barclays lifted their target price on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. William Blair began coverage on Cencora in a research report on Tuesday, April 28th. They set a “market perform” rating for the company. Finally, Morgan Stanley set a $342.00 price target on Cencora in a report on Friday, May 8th. Twelve research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $380.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.